This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.. Active years: 2019-2020.
Company Filing History:
Years Active: 2019-2020
Title: Innovations of Jinjia Wang in Pharmaceutical Development
Introduction
Jinjia Wang is a notable inventor based in Jiangsu, China, recognized for his contributions to pharmaceutical innovations. He has been instrumental in developing new crystal forms of dapagliflozin, a medication used to treat type II diabetes. His work has led to significant advancements in the quality and production processes of this important drug.
Latest Patents
Jinjia Wang holds two recent patents that showcase his innovative approach. The first patent is for a crystal form of a dapagliflozin intermediate and its preparation method. This invention allows for the purification of the intermediate to achieve a sample purity of 99.3% or more, which is crucial for enhancing the quality of dapagliflozin. The preparation process is noted for its simplicity and suitability for industrial production. The second patent involves a new dapagliflozin crystal form, along with its preparation method and therapeutic uses. This crystal form is particularly significant for its application in treating type II diabetes, demonstrating Wang's commitment to improving patient outcomes.
Career Highlights
Jinjia Wang is currently associated with Jiangsu Hansoh Pharmaceutical Group Co., Ltd., where he continues to drive innovation in pharmaceutical research and development. His expertise in the field has positioned him as a key player in the industry, contributing to advancements that benefit both the company and the broader medical community.
Collaborations
Wang collaborates with talented colleagues, including Xiang Li and Jun Yu, who contribute to the dynamic research environment at Jiangsu Hansoh Pharmaceutical Group. Their collective efforts enhance the potential for groundbreaking discoveries in the pharmaceutical sector.
Conclusion
Jinjia Wang's innovative work in the development of dapagliflozin crystal forms exemplifies the impact of dedicated inventors in the pharmaceutical industry. His contributions not only improve drug quality but also pave the way for better treatment options for patients with type II diabetes.